$MCK

McKesson, CD&R to Buy Option Care for $5.8B

McKesson Corp. and private equity firm Clayton, Dubilier & Rice will acquire Option Care Health Inc. for $5.8 billion, or $32.05 per share, a 37% premium. McKesson will own 49%, with CD&R as the controlling shareholder. Option Care, a major provider of home and outpatient infusion care, will retain its management team. The deal aligns with McKesson's strategy to expand specialty care services, potentially increasing its ownership over time.

Original reporting
Published Oct 7, 2026, 2:54 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 3:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
McKesson, CD&R to Buy Option Care for $5.8B — source image
Decision brief

The 30-second read

$MCKNeutralHigh
01

Why it matters

The transaction expands McKesson's service footprint while providing Option Care shareholders a premium exit, likely reshaping competitive dynamics in home and outpatient infusion markets.

02

Market read

A $5.8B M&A deal that could drive short‑term price moves in both stocks and signal broader industry consolidation.

03

What to watch

Regulatory approval risk and integration challenges could delay expected synergies.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

The deal combines a major drug distributor with the largest standalone infusion care provider, aiming to create a vertically integrated specialty care platform.

Company-level read

Ticker impact

$MCKNeutralHigh confidence
Context

McKesson announced a $5.8B acquisition of Option Care, committing $1.4B for a 49% stake.

Expected impact

potential modest downside as investors price in the cash outlay and integration risk

Evidence & confidence

Large M&A transaction with significant cash commitment; market typically reacts cautiously to acquisition spend.

$OPCHBullishHigh confidence
Context

Option Care Health stock jumped 33% after the acquisition announcement at $32.05 per share, a 37% premium.

Expected impact

upward pressure as the premium is priced in and the stock trades at a discount to the offer

Evidence & confidence

The announced premium and immediate price surge indicate strong buying interest; the deal is now certain.

Market effects

Accelerates consolidation in specialty infusion services, pressuring peers and distributors.

U.S. healthcare services sector may see increased M&A activity.

Highlights trend of drug distributors moving into service models worldwide.

Counterpoint

McKesson's cash outlay could strain balance sheet and dilute earnings, suggesting a short‑term pullback.

Key entities

  • McKesson Corp.

    U.S. drug distributor expanding into specialty care services.

  • Option Care Health Inc.

    Largest standalone provider of home and outpatient infusion care.

  • Clayton, Dubilier & Rice

    Co‑acquirer and controlling shareholder of Option Care.

Related articles

$MCKHighAI 9/10

McKesson, private equity firm buy home infusion company, Option Care Health

McKesson Corporation and private equity firm Clayton Dubilier & Rice (CD&R) agreed to acquire Option Care Health, a home infusion company, for $5.8 billion. McKesson will invest $1.4 billion for a 49% stake, with CD&R taking 51%. The deal values Option Care Health at $32.05 per share, a 36% premium over Monday's closing price. Once completed, Option Care Health will become private and delist from Nasdaq.

$LWHighAI 8/10

US Stock Movers: Lamb Weston, Option Care, Apogee Rally

Lamb Weston (LW) shares rose 11.85% after reporting Q1 sales of $1.67B and raising 2027 EBITDA guidance. Option Care (OPCH) jumped 32.8% on a $5.8B take-private deal. Apogee (APOG) gained 18.7% on strong Q2 earnings and raised FY2027 outlook. Constellation (CEG) surged 14.79% after a Google nuclear deal. RPM (RPM) rose 2.5% on record Q1 results.

$OPCHHighAI 9/10

Option Care Health (OPCH) Rockets as CD&R, McKesson Table 37% Premium Bid

Option Care Health (OPCH) surged 33% to $31.11 after announcing a $5.8B acquisition by CD&R and McKesson at a 37% premium. The deal, expected to close in 2027, values OPCH at $32.05 per share. The company will delist from Nasdaq. Hedge fund holdings fell 42% QoQ despite more funds establishing positions. Q3 earnings, due Nov 4, 2026, will not include guidance.

$OPCHMedAI 9/10

Option Care Stock Trades Below McKesson's Deal Price — Here's the Spread - Option Care Health (NASDAQ:OPC

Option Care Health (OPCH) agreed to be taken private by Clayton Dubilier & Rice and McKesson (MCK) for $32.05 per share, valuing the company at $5.8B. Shares traded at $31.05, leaving a $1.00 spread. The deal is expected to close in H1 2027, subject to approvals. McKesson will invest $1.4B for a 49% stake, with an option to buy out CD&R later. OPCH shares rose 32.78% on the news.